로봇 지원 수술 시스템 시장 - 세계 예측(2026-2032년)

The Robotic-assisted Surgery Systems Market is projected to grow by USD 15.80 billion at a CAGR of 9.48% by 2032.

Robotic-Assisted Surgery Systems Executive Summary

Robotic-assisted surgery systems are reshaping modern operating rooms by combining surgeon-controlled instrumentation, high-definition visualization, tremor filtration, motion scaling, navigation, and data-enabled workflow support. Across urology, gynecology, general surgery, cardiothoracic surgery, orthopedics, neurosurgery, and otolaryngology, these systems are being adopted to support minimally invasive procedures, improve dexterity in confined anatomical spaces, and standardize complex surgical tasks. The clinical value proposition is closely linked to smaller incisions, reduced blood loss, shorter hospital stays in selected procedures, and improved ergonomics for surgeons, while ongoing scrutiny remains focused on evidence quality, procedural appropriateness, total cost of ownership, training requirements, sterilization workflows, and cybersecurity resilience.

Demand for robotic-assisted surgery systems is supported by the global burden of chronic disease, aging populations, rising surgical volumes, and health system pressure to increase throughput without compromising patient safety. Hospitals and ambulatory surgical centers are increasingly evaluating robotic platforms not only as capital equipment but also as integrated surgical ecosystems that include instruments, accessories, simulation-based training, service contracts, software updates, imaging connectivity, and data governance. Regulatory agencies and professional societies continue to emphasize patient safety, credentialing, human factors engineering, and post-market surveillance, making evidence-based procurement and clinical governance central to sustainable adoption.

Transformative Shifts in the Robotic Surgery Landscape

The robotic-assisted surgery landscape is moving from single-platform adoption toward procedure-specific, digitally integrated, and value-based surgical robotics. Hospitals are no longer assessing robotic systems solely by technical capability; they are examining utilization rates, surgeon learning curves, instrument reprocessing, operating room turnover time, clinical outcomes, maintenance obligations, and interoperability with imaging, electronic health records, and perioperative analytics. This shift is creating stronger demand for modular systems, specialty-focused robots, open-console ergonomics, smaller footprints, and platforms designed for both large academic centers and space-constrained surgical facilities.

Another major transformation is the expansion of robotic surgery beyond traditional high-volume indications. Soft-tissue robotics remains central, but orthopedic robotic systems, spine navigation platforms, neurosurgical robots, catheter-based robotic systems, and image-guided interventional robotics are gaining relevance as precision medicine and minimally invasive care pathways mature. Training is also changing rapidly: virtual reality simulation, telementoring, digital case review, and competency-based credentialing are becoming essential to reduce variability and support safe scale-up. At the same time, procurement teams are placing greater emphasis on lifecycle economics, supply continuity, data security, and evidence demonstrating real-world benefits compared with conventional laparoscopy or manual techniques.

Cumulative Impact of AI on Surgical Robotics

Artificial intelligence is becoming a cumulative force in robotic-assisted surgery systems by enhancing imaging interpretation, surgical planning, intraoperative navigation, workflow automation, instrument tracking, decision support, and post-operative analytics. AI-enabled capabilities can help segment anatomical structures, identify surgical phases, detect deviations from standard workflows, and support training through objective performance metrics. In orthopedic and spine procedures, AI-linked planning and navigation can support implant positioning and alignment strategies, while in soft-tissue surgery, computer vision research is advancing tissue recognition, blood vessel mapping, and context-aware assistance.

The impact of artificial intelligence is not limited to intraoperative performance. AI can improve operating room scheduling, predict instrument needs, optimize maintenance planning, and support quality improvement programs through structured surgical data. However, adoption must be governed carefully because surgical AI involves high-stakes clinical decisions, sensitive patient data, algorithm transparency challenges, bias risks, and regulatory oversight. Industry leaders are increasingly expected to validate AI functions through rigorous clinical evidence, maintain explainability where feasible, protect data integrity, and ensure that automation augments rather than replaces surgeon judgment. The most durable opportunity lies in human-in-the-loop intelligence that improves consistency, safety, and learning across robotic surgery programs.

Key Regional Insights Across Robotic-Assisted Surgery Systems

Asia-Pacific is characterized by rapid hospital modernization, expanding specialty surgery capacity, and government interest in advanced medical technologies. China, Japan, South Korea, India, Australia, and ASEAN healthcare systems are investing in minimally invasive surgical infrastructure, surgeon training, and localized manufacturing capabilities, while patient access remains uneven between metropolitan centers and rural regions. Japan and South Korea show strong adoption potential due to technologically advanced hospitals and structured specialist training, whereas India and Southeast Asia present long-term opportunities tied to private hospital expansion, medical tourism, and growing disease burdens requiring surgical intervention.

North America remains one of the most mature environments for robotic-assisted surgery systems, supported by advanced hospital infrastructure, established reimbursement pathways for many procedures, strong specialist networks, and high procedural experience in urology, gynecology, general surgery, orthopedics, and thoracic care. The United States drives clinical innovation, training protocols, and evidence generation, while Canada emphasizes health technology assessment, surgical access, and public-system cost effectiveness. Latin America is progressing through selective adoption in major urban hospitals, with Brazil and Mexico leading broader procedural use as private healthcare networks, medical education centers, and specialty hospitals prioritize minimally invasive surgery. Europe demonstrates high clinical sophistication and strong regulatory oversight under the region's medical device framework, with Germany, France, the United Kingdom, Italy, and Spain focusing on evidence-based implementation, surgeon credentialing, and procurement discipline. The Middle East is advancing through tertiary care investments, specialty hospitals, and medical tourism ambitions, particularly in Gulf countries, while Africa remains at an earlier stage, with adoption concentrated in select urban referral centers and constrained by capital budgets, infrastructure readiness, specialist availability, and maintenance support.

Key Group Insights for Robotic Surgery Adoption

ASEAN countries are building robotic surgery capabilities through private hospital investment, regional medical tourism, and growing demand for minimally invasive treatment in urban centers. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines show differing levels of readiness, with advanced hospitals leading adoption while broader diffusion depends on workforce training, service availability, affordability, and national reimbursement priorities. GCC healthcare systems are investing in surgical robotics as part of broader strategies to develop high-acuity specialty care, reduce outbound medical travel, and strengthen domestic centers of excellence. These markets often emphasize premium hospital infrastructure, international accreditation, and advanced surgical programs, though long-term value depends on case volume, clinical governance, and sustainable training pipelines.

The European Union provides a highly regulated and evidence-oriented environment for robotic-assisted surgery systems, where medical device compliance, post-market clinical follow-up, procurement transparency, and data protection are central to adoption. EU hospitals increasingly evaluate robotic surgery through health technology assessment, clinical outcomes, and budget impact within public and mixed healthcare systems. BRICS economies present diverse opportunities: China and India combine large patient populations with expanding hospital networks; Brazil and South Africa show concentrated adoption in advanced urban centers; and Russia's activity is influenced by local healthcare modernization, procurement policy, and technology access. G7 countries generally represent mature, quality-driven markets with established surgical specialties, academic hospitals, and rigorous evaluation of clinical benefit, while NATO countries overlap significantly with advanced healthcare systems that prioritize resilient supply chains, cybersecurity, regulatory alignment, and surgical readiness across civilian and defense-linked medical infrastructure.

Key Country Insights in Robotic-Assisted Surgery Systems

The United States is a global reference point for robotic-assisted surgery systems due to high surgical specialization, broad hospital adoption, advanced training ecosystems, and extensive clinical research activity. Canada follows a more centralized and evidence-driven pathway, with adoption shaped by provincial health budgets, wait-time strategies, and health technology assessment. Mexico and Brazil are important Latin American adopters, with uptake concentrated in private hospitals, teaching institutions, and major metropolitan surgical centers where minimally invasive care and medical tourism support demand. The United Kingdom emphasizes value-based implementation within public and private settings, while Germany benefits from high hospital density, engineering expertise, and strong surgical specialization. France applies rigorous clinical and regulatory scrutiny, and Italy and Spain continue to integrate robotic surgery across urology, gynecology, general surgery, and thoracic procedures, particularly in leading university hospitals and regional centers.

Russia's robotic surgery environment is shaped by public healthcare priorities, domestic capability development, and access to advanced imported technologies. China is expanding robotic-assisted surgery through hospital modernization, domestic innovation, regulatory development, and rising demand for high-quality surgical care across large urban medical centers. India is advancing through private hospital chains, tertiary care institutions, surgeon training programs, and growing awareness of minimally invasive options, although affordability and geographic access remain central challenges. Japan has strong capabilities in precision engineering, aging-related surgical demand, and specialist adoption, while South Korea combines advanced digital health infrastructure, high hospital technology readiness, and medical device innovation. Australia demonstrates steady adoption through tertiary hospitals and private providers, with decisions shaped by clinical evidence, workforce training, and health system cost considerations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated innovation that addresses measurable surgical and operational needs rather than technology novelty alone. Product strategies should focus on procedure-specific performance, ergonomic design, reliable instrument ecosystems, seamless imaging integration, cybersecurity-by-design, and software architectures that can support safe updates and AI-enabled functionality. Evidence generation should include comparative clinical outcomes, learning-curve analysis, operating room efficiency, complication profiles, patient-reported outcomes, and lifecycle cost evaluation to support hospital procurement committees and regulatory stakeholders.

Commercial teams should develop flexible adoption models that reduce barriers for hospitals while preserving long-term service quality, including structured training, simulation, proctoring, maintenance support, and utilization optimization. Partnerships with academic hospitals, professional societies, and training centers can accelerate responsible adoption and improve surgeon competency. Leaders should also invest in regional customization, including language localization, instrument availability, service coverage, reimbursement alignment, and compliance with data protection laws. A disciplined approach to AI governance, post-market surveillance, supply chain resilience, and transparent clinical communication will be essential to build trust among surgeons, administrators, regulators, and patients.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public-domain and institutionally credible sources. The research process emphasizes regulatory documents, clinical guidelines, peer-reviewed medical literature, hospital technology assessment publications, government health statistics, medical device safety communications, professional society statements, and publicly available procurement and policy materials. Insights are synthesized across clinical, technological, regulatory, regional, and operational dimensions to identify adoption drivers, implementation barriers, and strategic priorities in robotic-assisted surgery systems.

The methodology excludes unsupported claims, speculative market sizing, and forward-looking market projections. Instead, it focuses on evidence-backed themes such as procedure expansion, minimally invasive surgery trends, AI integration, training requirements, regulatory oversight, health system readiness, and regional adoption dynamics. Qualitative triangulation is applied by comparing information across multiple source categories, including clinical evidence, regulatory guidance, hospital practice patterns, and healthcare infrastructure indicators. This approach supports a balanced understanding of robotic surgery adoption while avoiding overreliance on promotional claims or unverified assumptions.

Conclusion

Robotic-assisted surgery systems are entering a more mature phase defined by clinical evidence, digital integration, AI-enabled intelligence, and value-based adoption. Hospitals and surgical centers are increasingly looking beyond platform acquisition toward sustainable robotic surgery programs that combine patient selection, surgeon training, operating room efficiency, cybersecurity, service reliability, and measurable outcomes. The technology's role is expanding across specialties, but successful implementation depends on disciplined governance, rigorous validation, and alignment with healthcare system priorities.

Regional and country-level dynamics show that adoption is strongest where advanced infrastructure, trained specialists, supportive reimbursement or funding models, and evidence-based procurement converge. Artificial intelligence, simulation, data analytics, and image-guided workflows will continue to influence the evolution of surgical robotics, but trust will depend on safety, transparency, and human-centered design. Organizations that combine innovation with clinical credibility, affordability, training excellence, and resilient support networks will be best positioned to advance the next generation of robotic-assisted surgery systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Robotic-assisted Surgery Systems Market, by Components

• 7.1. Introduction
• 7.2. Instruments & Accessories
  • 7.2.1. Endoscopic Instruments
    • 7.2.1.1. Graspers
    • 7.2.1.2. Scissors
  • 7.2.2. Stapling Instruments
  • 7.2.3. Suturing Instruments
• 7.3. Services
  • 7.3.1. Consultancy Services
  • 7.3.2. Maintenance Services
    • 7.3.2.1. Corrective Maintenance
    • 7.3.2.2. Preventive Maintenance
  • 7.3.3. Training & Education
• 7.4. Systems
  • 7.4.1. Multi-Arm Robotic
  • 7.4.2. Single-Arm Robotic

8. Robotic-assisted Surgery Systems Market, by Applications

• 8.1. Introduction
• 8.2. Cardiothoracic
• 8.3. ENT
• 8.4. General Surgery
• 8.5. Gynecology
• 8.6. Neurosurgery
• 8.7. Orthopedic
• 8.8. Urology

9. Robotic-assisted Surgery Systems Market, by End Users

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Robotic-assisted Surgery Systems Market, by Region

• 10.1. Asia-Pacific
• 10.2. Europe
• 10.3. North America
• 10.4. Latin America
• 10.5. Africa
• 10.6. Middle East

11. Robotic-assisted Surgery Systems Market, by Group

• 11.1. NATO
• 11.2. G7
• 11.3. BRICS
• 11.4. European Union
• 11.5. ASEAN
• 11.6. GCC

12. Robotic-assisted Surgery Systems Market, by Country

• 12.1. China
• 12.2. United States
• 12.3. Japan
• 12.4. India
• 12.5. Germany
• 12.6. United Kingdom
• 12.7. Australia
• 12.8. France
• 12.9. South Korea
• 12.10. Italy
• 12.11. Canada
• 12.12. Russia
• 12.13. Brazil
• 12.14. Mexico
• 12.15. Spain

13. Competitive Landscape

• 13.1. Market Share Analysis, 2025
• 13.2. FPNV Positioning Matrix, 2025
• 13.3. Market Concentration Analysis, 2025
  • 13.3.1. Concentration Ratio (CR)
  • 13.3.2. Herfindahl Hirschman Index (HHI)
• 13.4. Recent Developments & Impact Analysis, 2025
• 13.5. Product Portfolio Analysis, 2025
• 13.6. Benchmarking Analysis, 2025

14. Company Profiles

• 14.1. Abbott Laboratories
• 14.2. Accuray Incorporated
• 14.3. avateramedical GmbH
• 14.4. Boston Scientific Corporation
• 14.5. Brainlab SE
• 14.6. CMR Surgical Ltd
• 14.7. Distalmotion SA
• 14.8. GE HealthCare Technologies Inc.
• 14.9. Globus Medical, Inc.
• 14.10. Intuitive Surgical, Inc.
• 14.11. Johnson & Johnson Services Inc.
• 14.12. Medicaroid Corporation
• 14.13. Medtronic PLC
• 14.14. meerecompany Inc.
• 14.15. MicroPort Scientific Corporation
• 14.16. Neocis Inc.
• 14.17. PROCEPT BioRobotics Corporation
• 14.18. Remote Robotics International, Inc.
• 14.19. Renishaw PLC
• 14.20. Shandong WEGO Surgery Robot Co., Ltd.
• 14.21. Shenzhen Futurtec Medical Co., Ltd.
• 14.22. Siemens Healthineers AG
• 14.23. Smith & Nephew plc
• 14.24. SRI International
• 14.25. SS Innovations International Inc.
• 14.26. Stereotaxis, Inc.
• 14.27. STERIS PLC
• 14.28. Stryker Corporation
• 14.29. Swisslog Healthcare by KUKA AG
• 14.30. Think Surgical, Inc.
• 14.31. TINAVI Medical Technologies Co., Ltd.
• 14.32. Vicarious Surgical Inc.
• 14.33. Virtual Incision Corporation
• 14.34. Zimmer Biomet Holdings, Inc.